Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from FOXO Technologies ( (FOXO) ) is now available.
On December 9, 2025, FOXO Technologies announced that its subsidiary, Myrtle Recovery Centers, was recognized by the Rural Health Association of Tennessee for its significant community impact. This recognition highlights Myrtle’s success in providing accessible behavioral health care across Tennessee, serving patients from 63 counties, and supports FOXO’s strategy to expand its services and facilities in rural areas.
Spark’s Take on FOXO Stock
According to Spark, TipRanks’ AI Analyst, FOXO is a Underperform.
FOXO Technologies receives a low overall stock score primarily due to significant financial challenges, including continuous net losses, high debt, and negative cash flows. The technical analysis also suggests bearish momentum. Although valuation metrics are poor, recent corporate actions, such as acquisitions and restructuring, provide some hope for future improvement. However, these are not sufficient to outweigh the current financial and operational challenges facing the company.
To see Spark’s full report on FOXO stock, click here.
More about FOXO Technologies
FOXO Technologies Inc. operates in the healthcare and biotechnology sectors, owning subsidiaries such as Rennova Community Health, Myrtle Recovery Centers, Vector BioSource, and FOXO Labs. These subsidiaries focus on community health services, behavioral health treatment, biologics and therapeutic services, and biotechnology innovations aimed at improving human health and lifespan.
Technical Sentiment Signal: Sell
Current Market Cap: $98.39K
Find detailed analytics on FOXO stock on TipRanks’ Stock Analysis page.